In this online, self-learning activity:
Osteoporosis is characterized by low bone mass and deterioration of bone tissues, which leads to an increased risk of skeletal fractures. Although osteoporosis is generally considered as a women’s health issue and often overlooked problem in men, osteoporosis in men is also an important public health issue, and its prevalence is increasing as the general population ages – rising to 11% in men by age 80. Around 1-2 million men in the United States have been estimated to have clinical osteoporosis, and an additional 8-13 million men identified to have low bone mass. In sum, 35% of men are considered to have low bone density by age 50, and that number rises to 53% by age 80.
This program has been designed to bring HCPs’ knowledge of the rationale behind prevention and treatment of male osteoporosis up to date and to improve their competence and performance in treating and preventing it.
The following HCPs: Primary care physicians and endocrinologists; physician assistants, nurse practitioners, and pharmacists who practice in endocrinology and internal medicine; and any other HCPs with an interest in or who clinically encounter male patients with osteoporosis.
Commercial Support Disclosure: This program is supported by an educational grant from Amgen.
This activity is free of charge.
Release Date: August 08, 2021 -- Expiration Date: August 08, 2023
Faculty: Peng Fan, MD
Faculty introduction, disclosures |
Introduction content: Review of male osteoporosis · Epidemiology
|
Treatment options · Consideration of underlying conditions and related treatment · Non-pharmacologic, nutritional, and over-the-counter recommendations and lifestyle modifications · Who should receive therapy (eu- vs. hypogonadal men, androgen-deprivation therapy, etc.) · Choice of agent, mono- vs. combination therapy [Learning objective #2]
· Patient case(s) [Learning objective #3] |
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #201759862
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physicians: For maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: Not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in this section, then it does NOT provide MOC credit.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-21-029-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Peng Thim Fan, MD, FACP, Clinical Professor of Medicine, Division of Rheumatology, David Geffen School of Medicine at UCLA, has received financial compensation for Speakers’ Bureau from Amgen (Prolia, Evenity), Abbvie, Pfizer, Sanofi, Genzyme Regeneron, Radius (Tymlos).
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Amgen.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Identifying and treating people at high risk for fracture from postmenopausal osteoporosis
Optimizing Primary and Secondary Fracture Prevention in Men with Osteoporosis
Postmenopausal osteoporosis risk stratification and treatment of those at high risk for fracture